Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMN Stock Forecast 2026-2027
$10.73
Current Price
$96.22M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMN Price Targets
+366.5%
To High Target of $50.05
+228.4%
To Median Target of $35.24
+70.2%
To Low Target of $18.26
PMN Price Momentum
-12.8%
1 Week Change
-39.0%
1 Month Change
-29.6%
1 Year Change
+57.1%
Year-to-Date Change
-73.0%
From 52W High of $39.75
+71.1%
From 52W Low of $6.27
📊 TOP ANALYST CALLS
Did PMN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProMIS is one of their latest high-conviction picks.
Latest PMN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PMN has a bullish consensus with a median price target of $35.24 (ranging from $18.26 to $50.05). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $10.73, the median forecast implies a 228.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMN Analyst Ratings
4
Buy
0
Hold
0
Sell
PMN Price Target Range
Low
$18.26
Average
$35.24
High
$50.05
Current: $10.73
Latest PMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 6, 2026 | Guggenheim | Eddie Hickman | Buy | Maintains | $35.00 |
| Dec 1, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Nov 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $4.00 |
| Nov 18, 2025 | Guggenheim | Eddie Hickman | Buy | Maintains | $5.00 |
| Jul 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $4.00 |
| May 12, 2025 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
| Apr 1, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $6.00 |
| Feb 26, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $N/A |
| Oct 3, 2023 | BTIG | Thomas Shrader | Buy | Initiates | $8.00 |
ProMIS Neurosciences, Inc. (PMN) Competitors
The following stocks are similar to ProMIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProMIS Neurosciences, Inc. (PMN) Financial Data
ProMIS Neurosciences, Inc. has a market capitalization of $96.22M with a P/E ratio of 7.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -521.6%.
Valuation Metrics
Market Cap
$96.22M
Enterprise Value
$96.48M
P/E Ratio
7.8x
PEG Ratio
-18.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
0.9x
Debt/Equity
0.0x
ROE
-521.6%
ROA
-176.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProMIS Neurosciences, Inc. (PMN) Business Model
About ProMIS Neurosciences, Inc.
What They Do
Develops targeted therapies for neurodegenerative diseases.
Business Model
ProMIS Neurosciences operates as a clinical-stage biotechnology company that generates revenue by developing and commercializing antibody therapies and therapeutic vaccines. The company utilizes proprietary algorithms to identify specific targets on misfolded proteins, enabling the creation of precision treatments for various neurodegenerative disorders, including Alzheimer’s disease and amyotrophic lateral sclerosis.
Additional Information
Founded in 2004 and rebranded in 2015, ProMIS Neurosciences is headquartered in Toronto, Canada, and has a presence in Cambridge, Massachusetts. The company is focused on advancing a range of therapies for conditions such as frontotemporal lobar degeneration and Huntington’s disease, positioning itself as a key player in the healthcare sector's precision medicine landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
10
CEO
Mr. Neil K. Warma M.B.A.
Country
Canada
IPO Year
2022
Website
www.promisneurosciences.comProMIS Neurosciences, Inc. (PMN) Latest News & Analysis
Latest News
Quick Summary
ProMIS Neurosciences (NASDAQ: PMN) will have CEO Neil Warma speak at the Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, in Toronto, focusing on Alzheimer's therapies.
Why It Matters
ProMIS Neurosciences' CEO's participation in a prominent healthcare conference may signal potential investor interest and could influence stock performance, particularly in the biotech space focused on Alzheimer's treatments.
Source: Newsfile Corp
Market Sentiment:
Neutral
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
28 days ago
Quick Summary
ProMIS Neurosciences' PRECISE-AD Phase 1b trial is fully enrolled, with six-month assessments due in Q2 2026. Interim analysis is expected in Q3 2026, and top-line data in early 2027.
Why It Matters
The enrollment completion of the PRECISE-AD trial and the promising safety profile of PMN310 could indicate potential for future drug approval, impacting ProMIS Neurosciences' stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences (Nasdaq: PMN) will present two scientific posters at the AD/PD™ 2026 conference in Copenhagen, focusing on its research into therapies for Alzheimer's and neurodegenerative disorders.
Why It Matters
ProMIS Neurosciences' presentation at a major conference signals progress in Alzheimer's research, potentially boosting investor confidence in its innovative therapies and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2 months ago
Quick Summary
ProMIS Neurosciences (Nasdaq: PMN) will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, featuring a fireside chat on February 11 at 9:30 AM ET.
Why It Matters
ProMIS Neurosciences' participation in the Guggenheim Biotech Summit highlights its ongoing engagement with investors, potentially signaling growth opportunities in Alzheimer's therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences has secured $175 million in funding to extend its cash runway into 2028, supporting its Phase 1b Alzheimer's study, with top-line data expected in mid to late 2026.
Why It Matters
ProMIS has secured $175 million, extending its cash runway into 2028, crucial for advancing its Alzheimer's study and bolstering investor confidence in future clinical milestones.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
4 months ago
Quick Summary
A significant Phase 1b study is underway to provide insights into early Alzheimer's disease, focusing on clinically and biologically relevant outcomes.
Why It Matters
Significant advancements in Alzheimer's research can lead to breakthroughs in treatment, potentially boosting stock values of biotech firms involved in this sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PMN Stock
What is ProMIS Neurosciences, Inc.'s (PMN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, ProMIS Neurosciences, Inc. (PMN) has a median price target of $35.24. The highest price target is $50.05 and the lowest is $18.26.
Is PMN stock a good investment in 2026?
According to current analyst ratings, PMN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMN stock?
Wall Street analysts predict PMN stock could reach $35.24 in the next 12 months. This represents a 228.4% increase from the current price of $10.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProMIS Neurosciences, Inc.'s business model?
ProMIS Neurosciences operates as a clinical-stage biotechnology company that generates revenue by developing and commercializing antibody therapies and therapeutic vaccines. The company utilizes proprietary algorithms to identify specific targets on misfolded proteins, enabling the creation of precision treatments for various neurodegenerative disorders, including Alzheimer’s disease and amyotrophic lateral sclerosis.
What is the highest forecasted price for PMN ProMIS Neurosciences, Inc.?
The highest price target for PMN is $50.05 from at , which represents a 366.5% increase from the current price of $10.73.
What is the lowest forecasted price for PMN ProMIS Neurosciences, Inc.?
The lowest price target for PMN is $18.26 from at , which represents a 70.2% increase from the current price of $10.73.
What is the overall PMN consensus from analysts for ProMIS Neurosciences, Inc.?
The overall analyst consensus for PMN is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.24.
How accurate are PMN stock price projections?
Stock price projections, including those for ProMIS Neurosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:37 AM UTC